Item 1. | Summary Term Sheet. |
Item 2. | Subject Company Information. |
Item 3. | Identity and Background of Filing Person. |
Item 4. | Terms of the Transaction. |
Item 5. | Past Contacts, Transactions, Negotiations and Agreements. |
Item 6. | Purposes of the Transaction and Plans or Proposals. |
Item 7. | Source and Amount of Funds or Other Consideration. |
Item 8. | Interests in Securities of the Subject Company. |
Item 9. | Persons/Assets Retained, Employed, Compensated or Used. |
Item 10. | Financial Statements. |
Item 11. | Additional Information. |
Item 12. | Exhibits. |
Exhibit Number | | | Description |
| | Offer to Purchase, dated July 25, 2022. | |
| | Letter of Transmittal. | |
| | Notice of Guaranteed Delivery. | |
| | Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. | |
| | Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. | |
| | Summary Advertisement as published in the Wall Street Journal, dated July 25, 2022. | |
(a)(2) | | | Not applicable. |
(a)(3) | | | Not applicable. |
(a)(4) | | | Not applicable. |
| | Joint Press Release issued by Sharps Compliance Corp. and Aurora Capital Partners, dated July 12, 2022 (incorporated by reference from Exhibit 99.1 to the Schedule TO-C filed by Purchaser and Parent dated July 12, 2022). | |
| | Press Release issued by Aurora Capital Partners, dated July 25, 2022. | |
(b) | | | Not applicable. |
| | Agreement and Plan of Merger, dated as of July 12, 2022 by and among Raven Houston Merger Sub, Inc., Raven Buyer, Inc. and Sharps Compliance Corp. (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Sharps with the SEC on July 13, 2022). | |
| | Amendment No. 1 to the Agreement and Plan of Merger, dated as of July 22, 2022 by and among Raven Houston Merger Sub, Inc., Raven Buyer, Inc. and Sharps Compliance Corp. | |
(d)(3)* | | | Confidentiality Agreement, dated as of May 9, 2022, 2022 by and between Revan Parent, Inc. and Sharps Compliance Corp. |
(d)(4)* | | | Exclusivity Agreement, dated as of June 18, 2022, by and between Aurora Capital Partners Management VI L.P. and Sharps Compliance Corp, as amended by the Amendment to the Original Exclusivity Agreement, dated July 3, 2022. |
| | Tender and Support Agreement, dated as of July 12, 2022, by and among Raven Buyer, Inc., Raven Houston Merger Sub, Inc., and certain directors and executive officers of Sharps Compliance Corp. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Sharps with the SEC on July 13, 2022). | |
(d)(6)* | | | Equity Commitment Letter, dated as of July 12, 2022, by and between Aurora Equity Partners VI L.P., Aurora Equity Partners VI-A L.P., Aurora Associates VI L.P., and Raven Buyer, Inc. |
(d)(7)* | | | Limited Guaranty, dated as of July 12, 2022, by and among Aurora Equity Partners VI L.P., Aurora Equity Partners VI-A L.P., and Aurora Associates VI L.P., in favor of Sharps Compliance Corp. |
| | Clean Team Agreement, dated May 9, 2022, between Raven Parent, Inc. and Sharps Compliance Corp. | |
(d)(9)* | | | Amendment dated as of July 3, 2022, to Exclusivity Agreement, dated as of June 18, 2022, by and between Aurora Capital Partners Management VI L.P. and Sharps Compliance Corp. |
(g) | | | Not applicable. |
(h) | | | Not applicable. |
| | Filing Fee Table. |
* | To be filed by amendment. |
Item 13. | Information Required by Schedule 13E-3. |
Date: July 25, 2022 | | | Raven Houston Merger Sub, Inc. | |||
| | | | |||
| | By: | | | /s/ Angela Klappa | |
| | Name: | | | Angela Klappa | |
| | Title: | | | Chief Executive Officer and President | |
| | | | |||
| | | | |||
| | Raven Buyer, Inc. | ||||
| | | | |||
| | By: | | | /s/ Angela Klappa | |
| | Name: | | | Angela Klappa | |
| | Title: | | | Chief Executive Officer and President |
THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59 P.M., NEW YORK CITY TIME, ON AUGUST 19, 2022, UNLESS THE OFFER IS EXTENDED OR TERMINATED. |
• | If you hold your Shares through a broker, dealer, bank, trust company or other nominee, you must contact such person and give instructions that your Shares be tendered. |
• | If you are a record holder (i.e., you hold certificates representing your Shares or hold your Shares in a book-entry/direct registration account maintained by Sharps’s transfer agent (such Shares, “DRS Shares”), in each case in your name), you must complete and sign the enclosed Letter of Transmittal according to its instructions and deliver it, together with any required signature guarantees, the certificates representing your Shares (except in the case of DRS Shares), and any other documents required by the Letter of Transmittal, to Computershare Trust Company, N.A., the depositary and paying agent for the Offer (the “Depositary & Paying Agent”), or tender your Shares by book-entry transfer. See Section 3 — “Procedure for Tendering Shares” of this Offer to Purchase for further details. |
Securities Sought | | | All issued and outstanding shares of common stock, par value $0.01 per share, of Sharps |
Price Offered Per Share | | | $8.75 per Share, net to the seller in cash, without interest and less any applicable withholding taxes |
Scheduled Expiration of the Offer | | | The time that is one minute following 11:59 p.m., New York City time, on August 19, 2022, unless the Offer is extended by Purchaser in accordance with the terms of the Merger Agreement |
Purchaser | | | Raven Houston Merger Sub, Inc., a wholly-owned subsidiary of Raven Buyer, Inc. |
• | prior to the expiration of the Offer, there being validly tendered (not counting as validly tendered any Shares tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee) and not validly withdrawn a number of Shares that, together with the Shares, if any, then owned by Parent or any of its subsidiaries, would represent at least one Share more than fifty percent (50%) of the number of Shares that are then issued and outstanding as of the expiration of the Offer on a fully diluted basis (which means, as of any time, the number of Shares outstanding, together with all Shares that Sharps would be required to issue pursuant to the conversion or exercise of all options, rights and securities convertible into or exercisable for Shares or otherwise, including after giving effect to the cancellation of the Sharps Options (as defined below) in accordance with Section 13 — “The Transaction Documents — The Merger Agreement — Treatment of Sharps Stock Options,” and regardless of the conversion or exercise price, the vesting schedule or other terms and conditions thereof) (the “Minimum Condition”); and |
• | prior to the expiration of the Offer, the applicable waiting period under the Merger Agreement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in respect of the transactions contemplated by the Merger Agreement having expired or having been terminated (the “HSR Condition”). |
• | determined that the Merger Agreement, the Offer, the Merger, and the other transactions contemplated by the Merger Agreement were fair to and in the best interests of Sharps and its stockholders, |
• | approved and declared advisable the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, upon the terms and subject to the conditions therein, and determined and resolved that the Merger would be governed by Section 251(h) of the DGCL, and |
• | resolved to recommend that Sharps’s stockholders accept the Offer and tender their Shares pursuant to the Offer. |
• | If you hold your Shares through a broker, dealer, bank, trust company or other nominee, you must contact such person and give instructions that your Shares be tendered. |
• | If you are a record holder (i.e., you hold certificates representing your Shares or DRS Shares, in each case in your name), you must complete and sign the enclosed Letter of Transmittal according to its instructions and deliver it, together with any required signature guarantees, the certificates representing your Shares (except in the case of DRS Shares) and any other documents required by the Letter of Transmittal, to the Depositary & Paying Agent or tender your Shares by book-entry transfer. See Section 3 — “Procedure for Tendering Shares” for further details. |
Terms of the Offer. |
Acceptance for Payment and Payment. |
Procedure for Tendering Shares. |
• | such tender is made by or through an Eligible Institution; |
• | a properly completed and duly executed Notice of Guaranteed Delivery in the form provided by us with this Offer to Purchase is received by the Depositary & Paying Agent (as provided below) prior to the Expiration Date; and |
• | the certificates representing all such tendered Shares (or a confirmation of a book-entry transfer of such Shares into the Depositary & Paying Agent’s account at the Book-Entry Transfer Facility), together with a properly completed and duly executed Letter of Transmittal together with, any required signature guarantees (or, in the case of a book-entry delivery of Shares, an Agent’s Message in lieu of the Letter of Transmittal) and any other required documents, are received by the Depositary & Paying Agent within two trading days after the date of execution of the Notice of Guaranteed Delivery. A “trading day” is any day on which Nasdaq is open for business. |
Withdrawal Rights. |
Material U.S. Federal Income Tax Considerations. |
(i) | the gain, if any, recognized on the exchange of the Shares for cash is effectively connected with the conduct by the Non-U.S. Holder of a trade or business in the United States (and, if certain income tax treaties apply, is attributable to the Non-U.S. Holder’s permanent establishment or fixed base in the United States), in which event (a) the Non-U.S. Holder will be subject to U.S. federal income tax as described above under “U.S. Holders,” and (b) if the Non-U.S. Holder is a corporation, it may also be subject to a branch profits tax at a rate of 30% of its effectively connected earnings and profits for the taxable year (or such lower rate as may be specified under an applicable income tax treaty); |
(ii) | the Non-U.S. Holder is an individual who was present in the United States for 183 days or more in the taxable year of the exchange of the Shares and certain other conditions are met, in which event the Non-U.S. Holder will be subject to tax at a rate of 30% (or such lower rate as may be specified under an applicable income tax treaty) on the gain from the exchange of the Shares net of U.S.-source losses from sales or exchanges of other capital assets recognized during taxable year of the exchange of Shares, provided that such Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses; or |
(iii) | Sharps is, or has been, a “U.S. real property holding corporation” within the meaning of Section 897(c)(2) of the Code and certain other requirements are satisfied. We do not expect Sharps to be treated as a United States real property holding corporation. |
Price Range of Shares. |
Year Ended June 30, 2022: | | | High | | | Low |
Fourth Quarter | | | $5.98 | | | $2.90 |
Third Quarter | | | $7.44 | | | $5.08 |
Second Quarter | | | $8.69 | | | $6.65 |
First Quarter | | | $10.47 | | | $8.22 |
Year Ended June 30, 2021: | | | High | | | Low |
Fourth Quarter | | | $18.67 | | | $10.22 |
Third Quarter | | | $15.47 | | | $9.06 |
Second Quarter | | | $10.06 | | | $5.45 |
First Quarter | | | $8.99 | | | $5.70 |
Possible Effects of the Offer on the Market for the Shares; Stock Exchange Listing(s); Registration under the Exchange Act; Margin Regulations. |
Certain Information Concerning Sharps. |
Certain Information Concerning Purchaser and Parent and the Aurora Funds. |
Source and Amount of Funds. |
Contacts and Transactions with Sharps; Background of the Offer. |
Purpose of the Offer; Plans for Sharps; Appraisal Rights. |
The Transaction Documents. |
• | reduce the Offer Price; |
• | change the form of consideration payable in the Offer (other than by adding consideration); |
• | reduce the number of Shares subject to the Offer; |
• | waive or change the Minimum Condition; |
• | add conditions or requirements to the Offer in addition to those set forth in Section 15 — “Conditions of the Offer”; |
• | extend or change the Expiration Date except as required or permitted by the Merger Agreement; or |
• | modify any condition to the Offer set forth in Section 15 — “Conditions of the Offer” or term of the Offer set forth in the Merger Agreement in a manner adverse to the holders of Shares. |
• | (i) declare, set aside, or pay any dividends on, or make any other distributions (whether in cash, stock, or property) in respect of, any of its capital stock or other equity interests, except for dividends by a directly or indirectly wholly-owned subsidiary of Sharps to its parent, (ii) purchase, redeem, or otherwise acquire shares of capital stock or other equity interests of Sharps or its subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests (except in accordance with agreements evidencing Sharps’s stock awards or tax withholdings and exercise price settlements upon the exercise of Sharps Options or vesting of Sharps RSAs), or (iii) split, combine, reclassify, or otherwise amend the terms of any of its capital stock or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for, shares of its capital stock or other equity interests; |
• | issue, deliver, sell, grant, pledge, or otherwise encumber or subject to any lien any shares of its capital stock or other equity interests or any securities convertible into, exchangeable for, or exercisable for any such shares or other equity interests, or any rights, warrants, or options to acquire, any such shares or other equity interests, or any stock appreciation rights, “phantom” stock rights, performance units, rights to receive shares of capital stock of Sharps on a deferred basis or other rights linked to the value of Shares, including pursuant to contracts as in effect on the date of the Merger Agreement (other than the issuance of Shares upon the exercise of Sharps Options outstanding on the Measurement Date (as defined in the Merger Agreement) in accordance with their terms as in effect on such date); |
• | amend or otherwise change, or authorize or propose to amend or otherwise change its certificate of incorporation or by-laws (or similar organizational documents); |
• | directly or indirectly acquire or agree to acquire (i) by merging or consolidating with, purchasing a substantial equity interest in, or a substantial portion of the assets of, making an investment in or loan or capital contribution to or in any other manner, any corporation, partnership, association, or other business organization or division thereof, (ii) any assets that are otherwise material to Sharps and its Subsidiaries, other than inventory of a particular SKU in an amount less than $25,000 (in the aggregate), or (iii) inventory of a particular SKU in excess of $25,000 (in the aggregate); |
• | directly or indirectly sell, lease, license, sell and leaseback, abandon, mortgage or otherwise encumber or subject to any lien (other than a Permitted Lien (as defined in the Merger Agreement)), or otherwise dispose in whole or in part of any of its properties, assets or rights or any interest therein with a value in excess of $25,000 (in the aggregate) except sales of inventory in the ordinary course of business consistent with past custom and practice; |
• | adopt or enter into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or other reorganization (other than the Merger); |
• | (i) incur, create, assume or otherwise become liable for, or repay or prepay (except as otherwise required by its terms as in effect on the date of the Merger Agreement), in each case, any Indebtedness, or amend, modify or refinance any Indebtedness (as defined in the Merger Agreement), or (ii) make any loans, advances, or capital contributions to, or investments in, any other person, other than Sharps or any direct or indirect wholly-owned subsidiary of Sharps; |
• | incur or commit to incur any capital expenditure or authorization or commitment with respect thereto in excess of $15,000 (in the aggregate) unless provided for in the capital expenditure budget delivered with the Merger Agreement; |
• | (i) pay, discharge, settle or satisfy any claims, liabilities or obligations (whether absolute, accrued, asserted or unasserted, contingent or otherwise) in excess of $15,000, in the aggregate, other than the payment, discharge or satisfaction in the ordinary course of business consistent with past custom and practice as required by the underlying terms of a contract as in effect on the date of the Merger Agreement or of claims, liabilities or obligations reflected or reserved against in the most recent financial statements (or the notes thereto) of Sharps included in the Company SEC Documents (as defined in the Merger Agreement) filed prior to the date of the Merger Agreement (for amounts not in excess of such reserves), (ii) cancel any Indebtedness owed to Sharps or any of its subsidiaries or (iii) waive, release, grant or transfer any right of material value; |
• | (i) modify or amend in any material respect, terminate, cancel, or extend any material contract (including any modification or amendment of any economic term (including, without limitation, any term related to pricing or volume commitments) or provision regarding duration, termination, indemnification or allocation of risk or liabilities among the parties) or (ii) enter into any contract that if in effect on the date of entry into the Merger Agreement would be a material contract; |
• | commence any action (other than an action as a result of an action commenced against Sharps or any of its subsidiaries), or compromise, settle or agree to settle any action (including any action relating to the Merger Agreement or the transactions contemplated thereby), other than: (i) compromises, settlements or agreements in the ordinary course of business consistent with past custom and practice (and which are not related to the Merger Agreement or the transactions contemplated thereby) that involve only the payment of money damages not in excess of $15,000, in the aggregate, in any case without the imposition of any equitable relief on, or the admission of wrongdoing by, Sharps or any subsidiary thereof, or (ii) to enforce Sharps’s rights under the Merger Agreement or in connection with the transactions contemplated thereby against Parent, Purchaser or the Aurora Funds in their capacity as guarantors under the Limited Guaranty (collectively, the “Guarantor”); |
• | change its financial accounting methods, principles, or practices, or revalue any of its material assets, except insofar as may have been required by generally accepted accounting principles in the United States (“GAAP”) or applicable law; |
• | settle or compromise any material liability for, or enter into any closing agreement in respect of, taxes; file any amended material tax return or claim for material tax refund; revoke or modify any material tax election; consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of material taxes (excluding extensions as a result of ordinary course extensions of time to file tax returns); enter into any material tax allocation agreement, tax sharing agreement or tax indemnity agreement; or change any annual tax accounting period; |
• | change its fiscal year; |
• | (i) increase the wages, salary or other compensation or benefits payable to any current or former director, officer, employee or independent contractor, (ii) grant or pay to any current or former director, officer, employee or independent contractor any severance, retention, change in control or termination pay, or modifications thereto or increases therein, (iii) grant or amend any equity or equity-based award (including in respect of stock options, stock appreciation rights, performance units, restricted stock or other stock-based or stock-related awards or phantom equity awards or the removal or modification of any restrictions in any Company Plan (as defined in the Merger Agreement) or awards made thereunder), (iv) adopt or enter into any collective bargaining agreement or other labor union contract, (v) take any action to accelerate the vesting, funding, or payment of any compensation or benefit under any Company Plan or other Contract, or (vi) adopt any new employee benefit or compensation plan or arrangement or amend or terminate any existing Company Plan, in each case other than as required by any Company Plan in effect as of the date of the Merger Agreement and previously disclosed to Parent or annual renewals of welfare benefit plans made in the ordinary course of business consistent with past custom and practice that does not materially increase the cost of such Company Plan; |
• | hire (i) employees at the executive level or higher or (ii) other than in the ordinary course of business consistent with past custom and practice, any other employees; |
• | terminate any employees of Sharps or its subsidiaries or otherwise cause any employees of Sharps or its subsidiaries to resign, in each case other than for cause or poor performance (documented in accordance with Sharps’s past practices); |
• | fail to keep in force insurance policies or replacement or revised provisions regarding insurance coverage with respect to the assets, operations, and activities of Sharps and its subsidiaries as currently in effect; |
• | terminate, allow to lapse or expire, suspend, modify or otherwise take any step to limit the effectiveness or validity of, or fail to maintain as valid and in full force and effect, any permit; |
• | renew or enter into any non-compete, exclusivity, non-solicitation, or similar agreement that would restrict or limit the operation of Sharps or its subsidiaries (other than any employee non-solicitation in the ordinary course of business consistent with past custom and practice and which would not materially limit the business or operations of Sharps and its subsidiaries); |
• | enter into any new line of business outside of its existing business; |
• | enter into any new lease or amend the terms of any existing lease of real property; |
• | (i) sell, assign, or transfer all or any portion of the material intellectual property owned by Sharps or any of its subsidiaries, (ii) grant any licenses of intellectual property except for non-exclusive licenses granted in the ordinary course of business consistent with past custom and practice, or (iii) abandon, permit to lapse, or cease to prosecute or maintain any of the Registered IP or any material Company Intellectual Property (each as defined in the Merger Agreement); |
• | spend, pay, incur or accrue fees, costs or expenses in excess of $15,000 (in the aggregate) in respect of marketing; |
• | spend, pay, incur or accrue fees, costs, or expenses in excess of $15,000 (in the aggregate) in respect of the implementation of any ERP system, resource, software or technology (whether as a capital expenditure or an operational expenditure); or |
• | authorize any of, commit, resolve or agree to take any of, the foregoing actions, including, without limitation, entering into a letter of intent, memorandum of understanding, agreement in principle, or term sheet with respect to the same. |
• | Any applicable waiting period (and any extension thereof) under the HSR Act relating to the transactions contemplated by the Merger Agreement, as well as any agreement not to close embodied in a “timing agreement” between the parties to the Merger Agreement and a governmental entity, will have expired or been terminated; |
• | No temporary restraining order, preliminary or permanent injunction, or other judgment, order or decree issued by any court of competent jurisdiction, or other legal restraint or prohibition will be in effect, and no law shall have been enacted, entered, promulgated, enforced or deemed applicable by any governmental entity that, in any such case, prohibits or makes illegal the consummation of the Merger; and |
• | Purchaser shall have irrevocably accepted for payment all Shares validly tendered (and not withdrawn) pursuant to the Offer. |
Dividends and Distributions. |
Conditions of the Offer. |
Certain Legal Matters; Regulatory Approvals. |
Fees and Expenses. |
Miscellaneous. |
Name and Position | | | Business Office Address | | | Present Principal Occupation or Employment and Employment History |
Angela Klappa Chief Executive Officer President Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Angela Klappa currently serves as the CEO of Curtis Bay Medical Waste Services, which she joined in February 2022. Previously, she was a senior executive at Aramark, specifically in the facilities services and industrial sector of Aramark Uniform Services. During her more than 20 year tenure there, she held numerous positions of increasing responsibility leading sales, operations and business development. |
| | | | |||
Andrew Wilson Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Andrew Wilson is a Partner at Aurora Capital Partners. Mr. Wilson joined Aurora Capital Partners in 2008. Previously, he was in the Investment Banking Division of Bank of America where he was a member of the Mergers & Acquisitions Group in New York. |
| | | | |||
Matthew Laycock Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Matthew Laycock is a Partner at Aurora Capital Partners. Mr. Laycock joined Aurora Capital Partners in 2004. Previously, he was at Castle Harlan and in the Investment Banking Division of J.P. Morgan where he was a member of the Industrials Group in New York. |
| | | | |||
Matthew Asperheim Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Matthew Asperheim is a Vice President of Aurora Capital Partners. Mr. Asperheim joined Aurora Capital Partners in 2014. Previously, he was in the Investment Banking Division of Houlihan Lokey where he was a member of the Healthcare Group in Chicago. |
| | | | |||
Charles Veniez Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Charles Veniez currently serves as Board Chair of West Coast Gate & Entry Systems, Board Chair at Curtis Bay Medical Waste Services, Board Member at Wholesale Produce Supply and is a Member of the Aurora Capital Executive Advisory Committee. Mr. Veniez is also managing Member of Mount Royal Holding, LLC. Prior to that he was President & CEO from 2014 to 2018 of Industrial Container Services. |
| | | | |||
Robert Weil Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Robert Weil is currently the Chief Financial Officer at Restaurant Technologies, which he joined in 2007. Prior to joining Restaurant Technologies, Mr. Weil had a 15 year career in the airline industry, holding various finance roles at Northwest Airlines from 1991 to 2000 and as Chief Financial Officer at MAIR Holdings from 2000 to 2007, the publicly traded parent company of Mesaba Airlines, a regional carrier for Northwest Airlines. |
Name and Position | | | Business Office Address | | | Present Principal Occupation or Employment and Employment History |
John Pencak Chief Financial Officer Treasurer | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | John Pencak currently serves as Chief Financial Officer and Treasurer at Curtis Bay Medical Waste Services. Mr. Pencak has held various positions of increasing responsibility in the management consulting industry for more than 25 years. |
| | | | |||
Allen Ruttenberg Chief Operating Officer Secretary | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Allen Ruttenberg currently serves as the Chief Commercial Officer at Curtis Bay Medical Waste Services, starting in 2021. Prior to his current role, Mr. Ruttenberg also served as District Manager at Curtis Bay Medical Waste Services from 2016 to 2018, and Vice President Sales from 2018 to 2020 and as Chief Operating Officer from 2020 until 2021. Prior to Curtis Bay Medical Waste Services, Mr. Ruttenberg held various positions of increasing responsibility in the environmental services industry. |
Name and Position | | | Business Office Address | | | Present Principal Occupation or Employment and Employment History |
Angela Klappa Chief Executive Officer President Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Angela Klappa currently serves as the CEO of Curtis Bay Medical Waste Services, which she joined in February 2022. Previously, she was a senior executive at Aramark, specifically in the facilities services and industrial sector of Aramark Uniform Services. During her more than 20 year tenure there, she held numerous positions of increasing responsibility leading sales, operations and business development. |
| | | | |||
Andrew Wilson Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Andrew Wilson is a Partner at Aurora Capital Partners. Mr. Wilson joined Aurora Capital Partners in 2008. Previously, he was in the Investment Banking Division of Bank of America where he was a member of the Mergers & Acquisitions Group in New York. |
| | | | |||
Matthew Laycock Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Matthew Laycock is a Partner at Aurora Capital Partners. Mr. Laycock joined Aurora Capital Partners in 2004. Previously, he was at Castle Harlan and in the Investment Banking Division of J.P. Morgan where he was a member of the Industrials Group in New York. |
| | | | |||
Matthew Asperheim Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Matthew Asperheim is a Vice President of Aurora Capital Partners. Mr. Asperheim joined Aurora Capital Partners in 2014. Previously, he was in the Investment Banking Division of Houlihan Lokey where he was a member of the Healthcare Group in Chicago. |
| | | | |||
Charles Veniez Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Charles Veniez currently serves as Board Chair of West Coast Gate & Entry Systems, Board Chair at Curtis Bay Medical Waste Services, Board Member at Wholesale Produce Supply and is a Member of the Aurora Capital Executive Advisory Committee. Charles is also managing Member of Mount Royal Holding, LLC. Prior to that he was President & CEO from 2014 from 2018 of Industrial Container Services. |
| | | |
Name and Position | | | Business Office Address | | | Present Principal Occupation or Employment and Employment History |
Robert Weil Director | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Robert Weil is currently the Chief Financial Officer at Restaurant Technologies which he joined in 2007. Prior to joining Restaurant Technologies, Mr. Weil had a 15 year career in the airline industry, holding various finance roles at Northwest Airlines from 1991-2000 and Chief Financial Officer at MAIR Holdings from 2000-2007, the publicly traded parent company of Mesaba Airlines, a regional carrier for Northwest Airlines. |
| | | | |||
John Pencak Chief Financial Officer Treasurer | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | John Pencak currently serves as Chief Financial Officer and Treasurer at Curtis Bay Medical Waste Services. Mr. Pencak has held various positions of increasing responsibility in the management consulting industry for more than 25 years. |
| | | | |||
Allen Ruttenberg Chief Operating Officer Secretary | | | 11611 San Vicente Blvd, Suite 800, Los Angeles, CA 90049 | | | Allen Ruttenberg currently serves as the Chief Commercial Officer at Curtis Bay Medical Waste Services, starting in 2021. Prior to his current role, he also served Curtis Bay MWS as District Manager, 2016-2018, V.P. Sales 2018-2020 and COO from 2020-2021. Prior to Curtis Bay MWS, Mr. Ruttenberg held various positions of increasing responsibility in the Environmental Services Industry. |
If delivering by Registered & Overnight Mail: | | | If delivering by First Class Mail: |
Computershare Trust Company, N.A. | | | Computershare Trust Company, N.A. |
Attn.: Corporate Actions Voluntary Offer 150 Royall Street, Suite V Canton, MA 02021 | | | Attn.: Corporate Actions Voluntary Offer P.O. Box 43011 Providence, RI 02940-3011 |
If delivering by Registered & Overnight Mail: | | | If delivering by First Class Mail: |
| | ||
Computershare Trust Company, N.A. Attn: Corporate Actions Voluntary Offer 150 Royall Street, Suite V Canton, MA 02021 | | | Computershare Trust Company, N.A. Attn: Corporate Actions Voluntary Offer P.O. Box 43011 Providence, RI 02940-3011 |
| DESCRIPTION OF SHARES TENDERED | | |||||||||
| Name(s) and Address(es) of Registered Holder(s) (Please fill in exactly as name(s) appear(s) on certificate(s) or DRS Account) | | | Shares Tendered (Attach additional list if necessary – See Instruction 3) | | ||||||
| | | Certificate Number(s)* | | | Total Number of Shares Represented by Certificate(s) or DRS Shares** | | | Number of Shares Tendered*** | | |
| | | | | | ||||||
| | | | | | ||||||
| | | | | | ||||||
| | | | | | ||||||
| | | | | | ||||||
| | | | | | ||||||
| | | | | | ||||||
| Total Shares | | |||||||||
| * Need not be completed by stockholders tendering by book-entry transfer or if Shares are held through a book-entry/direct registration account (a “DRS Account”) maintained by Resonant Inc.’s transfer agent (such Shares, “DRS Shares”). ** Need not be completed by stockholders tendering by book-entry transfer. *** Unless otherwise indicated, it will be assumed that all Shares described above are being tendered. See Instruction 4. | |
☐ | CHECK HERE IF SHARE CERTIFICATES HAVE BEEN MUTILATED, LOST, STOLEN OR DESTROYED. SEE INSTRUCTION 9. |
☐ | CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER INTO THE DEPOSITARY & PAYING AGENT’S ACCOUNT AT THE BOOK-ENTRY TRANSFER FACILITY AND COMPLETE THE FOLLOWING: |
Name of Tendering Institution: | | | ||||
Account Number: | | | ||||
Transaction Code: | | |
☐ | CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY & PAYING AGENT AND COMPLETE THE FOLLOWING: |
Name(s) of Tendering Stockholder(s): | | | ||||
Date of Execution of Notice of Guaranteed Delivery: , 2022 | ||||||
Name of Eligible Institution which Guaranteed Delivery: | | |
Name of Tendering Institution: | | | ||||
Account Number: | | | ||||
Transaction Code Number: | | |
Issue ☐ check ☐ certificates to: | |||||||||
Name: | | | |||||||
(Please Print) | |||||||||
Address: | | | |||||||
(Include Zip Code) | |||||||||
Taxpayer Identification Number: | | | |||||||
☐ | | | Credit DRS Shares not accepted for payment to the DRS Account set forth below: | ||||||
Account Name: | | |
Name: | | | |
(Please Print) | |||
Address: | | | |
(Include Zip Code) |
Sign Here: | | | |||||||
Sign Here: | | | |||||||
Signature(s) of Stockholder(s) | |||||||||
Dated , 2022 | |||||||||
Name(s): | | | |||||||
Business name, if different from above: | | | |||||||
(Please Print) | |||||||||
Capacity (Full Title): | | | |||||||
Address: | | | |||||||
(Include Zip Code) | |||||||||
Area Code and Telephone Number: | | |
Name of Firm: | | | |||||||
Address: | | | |||||||
(Include Zip Code) | |||||||||
Authorized Signature: | | | |||||||
Name: | | | |||||||
(Please Print) | |||||||||
Area Code and Telephone Number: | | | |||||||
Dated , 2022 |
(i) | such tender must be made by or through an Eligible Institution; |
(ii) | a properly completed and duly executed Notice of Guaranteed Delivery in the form provided by Purchaser with the Offer to Purchase must be received by the Depositary & Paying Agent prior to the Expiration Date; and |
(iii) | the certificates representing all physically delivered Shares, or a confirmation of a book-entry transfer into the Depositary & Paying Agent’s account at the Book-Entry Transfer Facility of all Shares delivered by book-entry transfer, together with a properly completed and duly executed Letter of Transmittal together with any required signature guarantees (or, in the case of a book-entry delivery of Shares, an Agent’s Message in lieu of the Letter of Transmittal) and any other required documents, must be received by the Depositary & Paying Agent within two trading days after the date of execution of the Notice of Guaranteed Delivery, all as provided in Section 3 of the Offer to Purchase. A “trading day” is any day on which the Nasdaq Stock Market is open for business. “Agent’s Message” means a message transmitted by the Book-Entry Transfer Facility to, and received by, the Depositary & Paying Agent and forming a part of a book-entry confirmation stating that the Book-Entry Transfer Facility has received an express acknowledgment from the participant in the Book-Entry Transfer Facility tendering the Shares that are the subject of such book-entry confirmation that such participant has received and agrees to be bound by the terms of the Letter of Transmittal and that Purchaser may enforce that agreement against the participant. |
If delivering by Registered & Overnight Mail: | | | If delivering by First Class Mail: |
Computershare Trust Company, N.A. Attn: Corporate Actions Voluntary Offer 150 Royall Street, Suite V Canton, MA 02021 | | | Computershare Trust Company, N.A. Attn: Corporate Actions Voluntary Offer P.O. Box 43011 Providence, RI 02940-3011 |
(Name of Firm) |
(Address) |
(Zip Code) |
(Authorized Signature) |
(Name and Title) |
(Area Code and Telephone Number) |
1. | The Offer to Purchase, dated July 25, 2022. |
2. | The Letter of Transmittal for your use in accepting the Offer and tendering Shares and for the information of your clients. |
3. | The Notice of Guaranteed Delivery to be used to accept the Offer if certificates representing Shares and all other required documents cannot be delivered to Computershare Trust Company, N.A. (the “Depositary & Paying Agent”), or if the procedures for book-entry transfer cannot be completed, prior to the expiration of the Offer. |
4. | A letter that may be sent to your clients for whose accounts you hold Shares registered in your name or in the name of your nominee, with space provided for obtaining such clients’ instructions with regard to the Offer. |
5. | Sharps’s Solicitation/Recommendation Statement on Schedule 14D-9. |
6. | Internal Revenue Service Form W-9. |
7. | A return envelope addressed to the Depositary & Paying Agent. |
| | Very truly yours, | |
| | ||
| | Raven Buyer, Inc. |
| | SIGN HERE | |
| | ||
Shares* | | | |
| | ||
Dated , 2022 | | | |
| | Signature(s) | |
| | ||
| | Name(s) | |
| | ||
| | Address(es) | |
| | ||
| | (Zip Code) | |
| | ||
| | Area Code and Telephone Number | |
| | ||
| | Taxpayer Identification or Social Security No. |
* | Unless otherwise indicated, it will be assumed that all Shares held for the undersigned’s account are to be tendered. |
RAVEN BUYER, INC.
|
||
By:
|
/s/ Angela Klappa
|
|
Name:
|
Angela Klappa
|
|
Title:
|
Chief Executive Officer and President
|
|
RAVEN HOUSTON MERGER SUB, INC.
|
||
By:
|
/s/ Angela Klappa
|
|
Name:
|
Angela Klappa
|
|
Title:
|
Chief Executive Officer and President
|
|
SHARPS COMPLIANCE CORP.
|
||
By:
|
/s/ W. Patrick Mulloy
|
|
Name:
|
W. Patrick Mulloy
|
|
Title:
|
Chief Executive Officer and President
|
Address for Notices:
|
|
c/o Aurora Capital Partners Management VI L.P.
|
|
11611 San Vicente Blvd, Suite 800
|
|
Los Angeles, California 90049
|
|
Attention: Robert K. West
|
|
Email: rkwest@auroracap.com
|
AURORA EQUITY
PARTNERS VI-A L.P.,
|
|||
a Delaware limited partnership
|
|||
By:
|
AURORA CAPITAL PARTNERS VI L.P.,
|
||
its General Partner
|
|||
By:
|
AURORA FUND VI UGP LLC,
|
||
its General Partner
|
|||
By:
|
|||
Name:
|
Robert K. West
|
||
Title:
|
Chief Financial Officer
|
Address for Notices:
|
|
c/o Aurora Capital Partners Management VI L.P.
|
|
11611 San Vicente Blvd, Suite 800
|
|
Los Angeles, California 90049
|
|
Attention: Robert K. West
|
|
Email: rkwest@auroracap.com
|
AURORA ASSOCIATES VI L.P.,
|
|||
a Delaware limited partnership
|
|||
By:
|
AURORA CAPITAL PARTNERS VI L.P.,
|
||
its General Partner
|
|||
By:
|
AURORA FUND VI UGP LLC,
|
||
its General Partner
|
|||
By:
|
|||
Name:
|
Robert K. West
|
||
Title:
|
Chief Financial Officer
|
Address for Notices:
|
|
c/o Aurora Capital Partners Management VI L.P.
|
|
11611 San Vicente Blvd, Suite 800
|
|
Los Angeles, California 90049
|
|
Attention: Robert K. West
|
|
Email: rkwest@auroracap.com
|
RAVEN BUYER, INC.
|
||
By:
|
||
Name:
|
||
Title:
|
1.
|
“Clean Team Information” shall mean Evaluation Materials (as defined in the Confidentiality Agreement) that (i) is communicated in written or other tangible form
which is marked “Clean Team Confidential,” at the time of disclosure, (ii) is communicated orally and is identified as Clean Team Information at the time of disclosure, or (iii) is posted to any “Clean Team” folder in any electronic data
rooms. Any failure to identify information in written or other tangible form as “Clean Team Confidential” at the time of initial disclosure will not be deemed to waive the producing party’s ability to designate the information
retroactively as “Clean Team Information.” A receiving Party that receives notice that a producing Party later wishes to designate previously-received information as “Clean Team Confidential,” that receiving Party shall take reasonable
steps to limit further disclosure of that information consistent with the terms of this Agreement.
|
2.
|
“Permitted Representatives” shall mean employees, directors and outside consultants and advisors of the Parties identified in Exhibit A. Any additions to Exhibit A
must be agreed to in writing by both Parties (which may include email). Outside consultants and advisors may be identified by the name of the entity and need not list specific individuals. In no event shall any Permitted Representative
currently participate in any direct day-to-day decision-making with respect to competitive activities such as setting prices or components of prices, sales, and marketing for medical waste disposal management, during the period in which he
or she has access to Clean Team Information and for two years following termination of the Potential Transaction or the abandonment of any negotiations relating to the Potential Transaction; provided
that if the Parties or their respective affiliates consummate the Potential Transaction, the obligations under this Paragraph (but not under the Confidentiality Agreement) shall terminate effective as of the closing of the Potential
Transaction.
|
3.
|
This Agreement is intended by the Parties to supplement the terms of the Confidentiality Agreement so as to avoid violations of laws with respect to competition and
to provide enhanced protection of commercially-sensitive information by providing for the procedures specified herein with respect to the treatment of Evaluation Material that constitutes Clean Team Information. Except as expressly
provided in this Agreement, the Parties intend that the Confidentiality Agreement shall continue in full force and effect and shall continue to govern the relationship of the Parties with respect to the treatment and use of Confidential
Information as well as other substantive and procedural issues; provided, however, that (i) the additional safeguards contained in this Agreement shall apply with respect to the treatment and use of Evaluation Material that constitutes
Clean Team Information and (ii) to the extent of any conflict between this Agreement and the Confidentiality Agreement, the provisions of this Agreement shall govern.
|
4.
|
Each Party will ensure that any Clean Team Information received by its Permitted Representatives (i) will be maintained and used in accordance with the
Confidentiality Agreement and (ii) will not be provided, discussed, exchanged, circulated, or otherwise furnished to or with any person who is not a Permitted Representative in any form other than as expressly permitted by this Agreement.
To this end, each Party shall prohibit further reproduction or distribution by recipients of such documents (other than reproduction by Permitted Representatives or distribution to Permitted Representatives).
|
5.
|
Each Party shall limit disclosure and access to Clean Team Information received from the other Party to the receiving Party’s Permitted Representatives, unless the
Clean Team Information has been redacted or aggregated by the producing Party’s Permitted Representatives in the form of a report (a “Clean Team Report”) and only if the outside antitrust counsel for the receiving Party has expressly
provided written approval for the disclosure of the Clean Team Report to the receiving Party’s non-Permitted Representatives on the basis that the information in the Clean Team Reports is sufficiently aggregated or redacted to prevent
disclosure of (a) competitively sensitive details or (b) other competitively sensitive Clean Team Information. For the avoidance of any doubt, Clean Team Reports shall be subject to the provisions of the Confidentiality Agreement.
|
6.
|
Each Party shall take such reasonable measures as may be appropriate to inform its outside consultants or advisors who may receive Clean Team Information of the
obligations of nonuse and nondisclosure set forth herein. Each Party will use commercially reasonable efforts to cause its Permitted Representatives to comply with these obligations.
|
7.
|
Permitted Representatives will preserve the confidential nature of Clean Team Information that they receive pursuant to this Agreement. Each Party and its
Permitted Representatives shall not disclose any of the Clean Team Information they receive to any other party, unless required, based upon the reasonable advice of their legal counsel, by law or court order (in which case such disclosure
shall only be made in accordance with the terms of the Confidentiality Agreement).
|
8.
|
Each Party shall use Clean Team Information only in connection with conducting due diligence, valuation, synergy and efficiency development, integration planning,
or the preparation of regulatory filings or submissions in connection with the Potential Transaction. No other use will be made by either Party or its Permitted Representatives of the Clean Team Information.
|
9.
|
All documents containing Clean Team Information that are required to be maintained in confidence under this Agreement shall remain the property of producing Party,
and all such documents and copies thereof shall be returned to the producing Party upon request. In the event the Potential Transaction does not take place, upon the request of the producing Party, the receiving Party and its Permitted
Representatives shall promptly return or destroy, to the extent technically and reasonably possible, all documents containing Clean Team Information of the producing Party. For the avoidance of doubt, the receiving Party is not required to
destroy or return copies of documents containing Clean Team Information that are stored on disaster-recovery or other similar archives.
|
10.
|
The obligations of confidentiality and nonuse related to the Clean Team Information received under this Agreement shall be binding and, in the event the Potential
Transaction does not take place, continue in force until the date on which the Confidentiality Agreement terminates; provided that if the Parties and/or their affiliates execute definitive
agreements with respect to the Potential Transaction, all of the obligations hereunder (but not under the Confidentiality Agreement), shall terminate effective as of the closing of the definitive agreements, in the event that such date is
sooner than the date that the NDA terminates.
|
On behalf of Sharps Compliance Corp.:
|
||
/s/ Pat Mulloy
|
||
Name:
|
Pat Mulloy
|
|
Title:
|
Chief Executive Officer
|
|
Date:
|
6/27/22 |
|
On behalf of Raven Parent, Inc.:
|
||
/s/ Matt Asperheim
|
||
Name:
|
Matt Asperheim
|
|
Title:
|
Director
|
|
Date:
|
6/27/22 |
Name
|
Title
|
Matthew Asperheim
|
Partner, Aurora Management Partners L.P.
|
Ben Brothers
|
Associate, Aurora Management Partners L.P.
|
Matthew Laycock
|
Partner, Aurora Management Partners L.P.
|
Andrew Wilson
|
Partner, Aurora Management Partners L.P.
|
Charles Veniez
|
Director, Raven Parent, Inc.
|
Chris Jones
|
Vice President of M&A, Curtis Bay Medical Waste Services
|
External Advisors
|
Gibson, Dunn & Crutcher, LLP
|
Aurora Management Partners L.P.
|
Ernst & Young Global Limited
|
Transaction Valuation*
|
Fee Rate
|
Amount of Filing Fee**
|
|
Fees to Be Paid
|
$178,428,836.25
|
0.0000927
|
$16,540.35
|
Fees Previously Paid
|
$0.00
|
$0.00
|
|
Total Transaction Valuation
|
$178,428,836.25
|
||
Total Fees Due for Filing
|
$16,540.35
|
||
Total Fees Previously Paid
|
$0.00
|
||
Total Fee Offsets
|
$0.00
|
||
Net Fee Due
|
$16,540.35
|
* |
The transaction valuation is estimated for purposes of calculating the amount of the filing fee only. The transaction valuation was estimated by multiplying
(i) 20,391,867 Shares (which is based on the following information provided by Sharps Compliance Corp. (“Sharps”) as of July 22, 2022: (1) 19,787,790 issued and outstanding shares of common stock of Sharps to be acquired by Raven Buyer,
Inc., par value $0.01 per share (the “Shares”), including (A) 83,320 Shares issuable upon the settlement of unvested restricted stock awards that are granted to employees under the Sharps Compliance Corp. 2010 Stock Plan, and (B) 14,766
Shares issuable upon the settlement of unvested restricted stock awards that are granted to directors under the Sharps Compliance Corp. 2010 Stock Plan, plus (3) 604,077 Shares issuable upon exercise of stock options), by (ii) the net offer price of $8.75 per Share. The calculation of the transaction value is based on information provided by Sharps as of
July 22, 2022.
|
** |
The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year
2022 beginning on October 1, 2021, issued on August 23, 2021, by multiplying the transaction valuation by 0.0000927.
|
RAVEN PARENT, INC.
|
|
By: /s/ Andrew Wilson
Name: Andrew Wilson
Title: President and Chief Executive Officer
|
|
Addresses for Notice:
|
c/o Aurora Capital Partners Management VI, L.P.
11611 San Vicente Blvd., Ste. 800 Los Angeles, CA 90049 Attn: Andrew Wilson Email: awilson@auroracap.com>
|
SHARPS COMPLIANCE CORP.
|
|
By: /s/ Sharon R. Gabrielson
Name: Sharon R. Garbielson
Title: Chair of the Board
|
|
Addresses for Notice:
|
Sharps Compliance Corp.
9220 Kirby Drive, Suite 500
Houston, Texas 77054
Attention: Chair of the Board
Email: gabrielsonsr@gmail.com
with copy to (which shall not constitute notice):
Brandon Byrne
Norton Rose Fulbright US LLP
2200 Ross Avenue, Suite 3600
Dallas, Texas 75201
Email: brandon.byrne@nortonrosefulbright.com
|
Notices to the Company:
Sharps Compliance Corp.
9220 Kirby Drive, Suite 500
Houston, Texas 77054
Attention: W. Patrick Mulloy
Email: pmulloy@sharpsinc.com
|
With copies (which shall not constitute notice) to:
Norton Rose Fulbright US LLP
2200 Ross Avenue, Suite 3600
Dallas, Texas 75201-7932
Attention: Brandon Byrne
Email: brandon.byrne@nortonrosefulbright.com
|
Notices to Guarantors or Parent:
c/o Aurora Capital Partners Management VI L.P.
11611 San Vicente Blvd, Suite 800
Los Angeles, CA 90049
Attention: Robert K. West
E‑mail: rkwest@auroracap.com
|
With copies (which shall not constitute notice) to:
Gibson, Dunn & Crutcher LLP
2029 Century Park East, Suite 4000
Los Angeles, CA 90067
Attention: Ari B. Lanin; Daniela Stolman
E‑mail: alanin@gibsondunn.com; dstolman@gibsondunn.com
|
AURORA ASSOCIATES VI L.P.,
|
|||
a Delaware limited partnership
|
|||
By:
|
AURORA CAPITAL PARTNERS VI L.P.,
|
||
its General Partner
|
|||
By:
|
AURORA FUND VI UGP LLC,
|
||
its General Partner
|
|||
By:
|
|||
Name:
|
Robert K. West
|
||
Title:
|
Chief Financial Officer
|
Address for Notices:
|
||
c/o Aurora Capital Partners Management VI L.P.
|
||
11611 San Vicente Blvd, Suite 800
|
||
Los Angeles, CA 90049
|
||
Attention:
|
Robert K. West
|
|
Email:
|
rkwest@auroracap.com
|
ACCEPTED BY:
|
||
THE COMPANY:
|
||
SHARPS COMPLIANCE CORP.,
|
||
a Delaware corporation
|
||
By:
|
||
Name:
|
||
Title:
|